EAU 2018

EAU 2018: Results from the TRACERx Renal Study: Deterministic Routes to Tumor Progression in Clear Cell Renal Cell Carcinoma

Copenhagen, Denmark (UroToday.com) Dr. Samra Turajlic from the Francis Crick Institute in London provided initial results from the TRACERx Renal study. Dr. Turajlic opened by noting that there are a wide range of clinical phenotypes/outcomes among patients with advanced renal cell carcinoma, including (i) indolent disease – oligo metastatic progression among which patients may benefit from cytoreductive nephrectomy and oligo-metastasectomy, and (ii) aggressive disease – disseminated metastases and early death among which patients do not benefit from cytoreductive nephrectomy and have a poor response to therapy. There are three important clinical dilemmas according to Dr. Turajlic: (i) treatment of metastatic disease, which may include surgery to defer systemic therapy, (ii) adjuvant therapy for high-risk disease, (iii) active surveillance of small renal masses.

EAU 2018: Latest in Medical Treatment - Renal Cell Cancer

Copenhagen, Denmark (UroToday.com)  Dr. Bedke gave an overview of the latest advancements in renal cell carcinoma (RCC). He discussed on the topics of cytoreductive nephrectomy (CN), adjuvant therapy (AT) and changes in 1st line therapy for advanced metastatic RCC.

EAU 2018: Analysis shows influential US prostate study not representative of real-world patients

Truckee, CA (UroToday.com) An analysis of 3 US cancer databases has shown that a major US study comparing surgery with observation in early prostate cancer patients, the PIVOT study, used patients which didn’t properly reflect the average US patient. Researchers found that patients in the PIVOT trial were between 3 and 8 times more likely to die than real-world patients. This may call into question the conclusions of the study, which are now being implemented in the US and worldwide. It was presented at the European Association of Urology congress (EAU18) in Copenhagen on 17 March, following publication as a letter in the peer-reviewed journal, European Urology1.

EAU 2018: Hormone-Naive Prostate Cancer

Copenhagen, Denmark (UroToday.com)  Dr. Joniau gave an overview of hormone-naïve prostate cancer (HNPC). Approximately 5% of the screened population present with de novo metastatic prostate cancer. This represents 1/3 of the prostate cancer (PC) death in the USA each year. The remaining 2/3 of patients relapse after prior localized therapy. They undergo rapid progression to metastasis, with transformation of HSPC to castrate resistant prostate cancer (CRPC), and then to death.  The median time from radical prostatectomy to PSA failure is 24 months (12-44). The median time from PSA failure to metastasis is 32 months (2-129), and finally the median time from metastasis to PC specific mortality is 82 months (7-181). Overall, from PC relapse to PC specific death the median time is 132 months (12-204).

EAU 2018: Highlights from ASCO-GU 2018

Copenhagen, Denmark (UroToday.com)  Dr. Nguyen gave a talk summarizing the recent GU-ASCO 2018 meeting which took place in San-Francisco, USA, earlier this year.

EAU 2018: Castration Resistant Prostate Cancer

Copenhagen, Denmark (UroToday.com)  Dr. Evans gave an overview of the hottest and latest news in the medical treatment of castrate resistant prostate cancer (CRPC).  In metastatic CPRC (MCRPC), plasma circulating tumor DNA (ctDNA) has emerged as a tool to sample the tumor genome.  Up until recently, no systematic comparisons of matched liquid and solid biopsies were performed to enable ctDNA profiling to replace direct tissue sampling.

EAU 2018: Urothelial Cancer – A Year in Highlights

Copenhagen, Denmark (UroToday.com)  Dr. Powles gave an overview of the recent highlights and advances in the treatment of urothelial cancer. Immune checkpoint inhibitors (ICI) are the biggest advancement in urothelial cancer and the licensed ICI in metastatic urothelial cancer (MUC) are shown in figure 1.